Concerted Action Polyp Prevention

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN83743312

Enrollment

400

Registered

2005-09-15

Start date

1993-01-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Familial Adenomatous Polyposis (FAP) Cancer Familial adenomatous polyposis (FAP)

Interventions

Factorial design of: A. 600 mg Aspirin and 30 g Resistant Starch B. Placebo Aspirin and 30 g Resistant Starch C. 600 mg Aspirin and 30 g Placebo Starch D. Placebo Aspirin and Placebo Starch

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Known carriers of familial adenomatous polyposis (FAP), either by molecular genetic analysis or by phenotypic features 2. Over 10 years of age with an intact colon

Exclusion criteria

Exclusion criteria: 1. Already taking Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 2. Partial Resection 3. If over 21 years of age - to take treatment for 1 year only

Design outcomes

Primary

Measure	Time frame
1. Age at colectomy 2. Reduction in size of polyps 3. Changes in crypt cell proliferation	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026